• 제목/요약/키워드: drug efficacy

검색결과 946건 처리시간 0.027초

The anti-parasitic efficacy of ivermectin and pyrantel pamoate compound against canine Toxocara canis and Trichuris vulpis

  • Youn, Heejeong;Ra, Jeong Chan;Kim, Byung Ki;Bae, Bokyoung;Lim, Yong Suk;Kim, Kyong Hee;Lee, Kyong-Eun
    • 대한수의학회지
    • /
    • 제51권4호
    • /
    • pp.289-295
    • /
    • 2011
  • Toxocara (T.) canis and Trichuris (T.) vulpis are very important canine parasitic nematodes. T. canis parasitize in small intestine and T. vulpis parasitize in large intestine. In order to control of these nematodes, ivermectin and pyrantel pamoate compound was applied to the dogs infected with these parasites naturally and artificially. This drug was composed of $68.0{\mu}g$ of ivermectin and 57.0 mg of pyrantel pamoate for small animal, $136.0{\mu}g$ of ivermectin and 114.0 mg of pyrantel pamoate for middle animal, and $272.0{\mu}g$ of ivermectin and 227.0 mg of pyrantel pamoate for large animal. Ivermectin in this drug is activity to nematodes and ectoparisites. Pyrantel pamoate in this drug is also activity to nematodes. In this experiment, this drug had a good efficacy against T. canis and T. vulpis in the infected dogs.

Sex Differences in Cancer: Epidemiology, Genetics and Therapy

  • Kim, Hae-In;Lim, Hyesol;Moon, Aree
    • Biomolecules & Therapeutics
    • /
    • 제26권4호
    • /
    • pp.335-342
    • /
    • 2018
  • The incidence and mortality of various cancers are associated with sex-specific disparities. Sex differences in cancer epidemiology are one of the most significant findings. Men are more prone to die from cancer, particularly hematological malignancies. Sex difference in cancer incidence is attributed to regulation at the genetic/molecular level and sex hormones such as estrogen. At the genetic/molecular level, gene polymorphism and altered enzymes involving drug metabolism generate differences in cancer incidence between men and women. Sex hormones modulate gene expression in various cancers. Genetic or hormonal differences between men and women determine the effect of chemotherapy. Until today, animal studies and clinical trials investigating chemotherapy showed sex imbalance. Chemotherapy has been used without consideration of sex differences, resulting in disparity of efficacy and toxicity between sexes. Based on accumulating evidence supporting sex differences in chemotherapy, all clinical trials in cancer must incorporate sex differences for a better understanding of biological differences between men and women. In the present review, we summarized the sex differences in (1) incidence and mortality of cancer, (2) genetic and molecular basis of cancer, (3) sex hormones in cancer incidence, and (4) efficacy and toxicity of chemotherapy. This review provides useful information for sex-based chemotherapy and development of personalized therapeutic strategies against cancer.

A Randomized single blind controlled clinical trial on safety and efficacy of a Unani formulation (Itrifal-e-Sagheer) in dyslipidemia

  • Alam, Sazid;Alam, MD Anzar;Quamri, MA;Sofi, Ghulamuddin;Khan, Mohd. Qudratullah;Ansari, Shabnam
    • 셀메드
    • /
    • 제10권1호
    • /
    • pp.8.1-8.7
    • /
    • 2020
  • Aim:'Itrifal-e-Sagheer', a compound Unani formulation has been indicated in disease conditions simulating dyslipidemia. The present study was done to substantiate the efficacy of 'Itrifal-e-Sagheer' in dyslipidemia on scientific parameters. Materials and methods: A randomized, single blind, controlled, clinical trial was carried out on 30 patients of dyslipidemia who were randomly allocated into test (n = 15) or control (n = 15) groups. The test drug, Itrifal-e-Sagheer and control drug, Abana® were given to respective group for 45 days along with lifestyle modification. Results: The test drug significantly alleviated the symptoms of subjective parameters (palpitation, breathlessness and weight gain) (p<0.05). There was statistically significant reduction in lipid profile of the patients in test group (p<0.05) than control drug treatment. Conclusion: The study evidenced that Itrifal-e-Sagheer is potentially effective and safe in the treatment of dyslipidemia. However, a multicentric study with robust study design is required to generalize the results.

Concise Clinical Review of Hematologic Toxicity of Linezolid in Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis: Role of Mitochondria

  • Oehadian, Amaylia;Santoso, Prayudi;Menzies, Dick;Ruslami, Rovina
    • Tuberculosis and Respiratory Diseases
    • /
    • 제85권2호
    • /
    • pp.111-121
    • /
    • 2022
  • Multidrug-resistant tuberculosis (MDR-TB) is caused by an organism that is resistant to both rifampicin and isoniazid. Extensively drug-resistant TB, a rare type of MDR-TB, is caused by an organism that is resistant to quinolone and one of group A TB drugs (i.e., linezolid and bedaquiline). In 2018, the World Health Organization revised the groupings of TB medicines and reclassified linezolid as a group A drug for the treatment of MDR-TB. Linezolid is a synthetic antimicrobial agent in the oxazolidinone class. Although linezolid has a good efficacy, it can cause substantial adverse events, especially hematologic toxicity. In both TB infection and linezolid mechanism of action, mitochondrial dysfunction plays an important role. In this concise review, characteristics of linezolid as an anti-TB drug are summarized, including its efficacy, pathogenesis of hematologic toxicity highlighting mitochondrial dysfunction, and the monitoring and management of hematologic toxicity.

Pharmacogenomics in Drug Discovery and Development

  • Ahn, Chul
    • Genomics & Informatics
    • /
    • 제5권2호
    • /
    • pp.41-45
    • /
    • 2007
  • Pharmacogenomics is the study that examines how genetic variations affect the ways in which people respond to drugs. The ways people respond to drugs are complex traits that are influenced by many different genes. Pharmacogenomics intends to develop rational means of optimizing drug therapy, with respect to the patients' genotype, to maximize efficacy with minimal adverse drug reactions. Pharmacogenomics has the potential to revolutionize the practice of medicine, and promises to usher in an area of personalized medicine, in which drugs and drug combinations are optimized for each individual's unique genetic makeup. Indeed, pharmacogenomics is exploited as an essential step for target discovery and drug development in the pharmaceutical industry. The goal of the personalized medicine is to get the right dose of the right drug to the right patient at the right time. In this article, we will review the use of pharmacogenomics in drug discovery and development.

향정신성약물의 치료적 약물농도 검사 (Therapeutic Drug Monitoring (TDM) of Psychotropic Drugs)

  • 양병환
    • 생물정신의학
    • /
    • 제5권1호
    • /
    • pp.56-65
    • /
    • 1998
  • Clinicians can use therapeutic drug monitoring(TDM) to optimise dosage decisions with psychotropic drugs, in order to maximize efficacy and prevent toxicity, especially when individuals are nonresponsive to treatment or vulnerable to adverse reactions with standard doses because age, disease states or drug interactions. Currently, therapeutic drug concentrations have been established for the TCA and lithium. There is also evidence for the usefulness of TDM with carbamazepine, valproic acid and some antipsychotic drugs. However for most psychotropic drugs this approach remains experimental. TDM-assisted psychiatric treatment is potentially useful and cost effective, particularly when applied by psychiatrists who are knowledgeable of pharmacokinetics and pharmacodynamics.

  • PDF

의료기기 허가.기술문서 원자재 작성 가이드라인 개발 (The Development for guideline of raw matrials on technical document of Medical Device)

  • 박기정;유규하;이성희;이창형;정진백;이재근;허찬회;김형범;최민용;김용우;황상연;정재훈;구자중;홍혜경;임경택;강세구;곽지영
    • 대한의용생체공학회:의공학회지
    • /
    • 제31권6호
    • /
    • pp.434-437
    • /
    • 2010
  • For approval of medical devices manufactured or imported, submission of technical documents as well as the application form is required. The manufacturer (or importer) should properly identify the raw materials the applied product is made of and the manufacturing processes the product undergoes before it is shipped in the application form. In the technical documents, scientific data to evaluate the efficacy, safety, and quality of the applied product that has been described in the application form should be provided. Therefore, identifying the raw materials that were used for the parts of the applied product and describing the physical and chemical characteristics of the raw materials are quite important and essential in ensuring the efficacy, safety, and quality of the applied product. To describe the physical and chemical characteristics of the raw materials correctively, the applicant is required to have broad knowledge in the scientific fields such as chemical, polymer, metal, and ceramic science and engineering. But most of the applicant are not experts in these fields, so that the description in the application form often includes wrong and improper descriptions. Thus, we developed a guideline which explains the raw materials for medical devices, show the their examples. The purpose of this description guideline is to help the applicant properly completing the "Raw materials or constituents and their volumes" part in the application form.

Surface modulation of long term drug releasing microparticulates for optimization of release kinetics

  • Hwang, Jeong-Hyo;Song, Hye-Won;Lee, Seung-Jin
    • 대한약학회:학술대회논문집
    • /
    • 대한약학회 2003년도 Proceedings of the Convention of the Pharmaceutical Society of Korea Vol.1
    • /
    • pp.301-302
    • /
    • 2003
  • With the aim of obtaining the early bone regeneration efficacy, poly (L-lactide) particulates were developed as a long-term drug carrier system.Biodegradable microparticulates have been used extensively as drug delivery devices. However, problems like poor encapsulation efficiencies of the drugs and complicated fabrication process are still remained to be solved. (omitted)

  • PDF

반추수의 내부기생충에 대한 신종 광범위구충제의 구충효과 - I. Albendazole (Valbazen-B)의 구충효과 (Field Trials on the Efficacy of New Broad-Spectrum Anthelmintics 1. Anthelmintic Efficacy of Albendazole Against Gastrointestinal Nematodes, Trematodes and Cestode in Korean Native Goat)

  • 서명득;이순선;조희택
    • 대한수의사회지
    • /
    • 제21권10호
    • /
    • pp.605-611
    • /
    • 1985
  • The anthelmintic efficacy of Albendazole(Valbazen-B) at a dose rate of 10mg /kg of body weight was tested in naturally infected Korean native goats against gastrointestinal nematodes, trematodes and cestode. The drug was administered with Valbazen-B bolus

  • PDF

Arsenic Trioxide Promotes Paclitaxel Cytotoxicity in Resistant Breast Cancer Cells

  • Bakhshaiesh, Tayebeh Oghabi;Armat, Marzie;Shanehbandi, Dariush;Sharifi, Simin;Baradaran, Behzad;Hejazi, Mohammad Saeed;Samadi, Nasser
    • Asian Pacific Journal of Cancer Prevention
    • /
    • 제16권13호
    • /
    • pp.5191-5197
    • /
    • 2015
  • A partial response or resistance to chemotherapeutic agents is considered as a main obstacle in treatment of patients with cancer, including breast cancer. Refining taxane-based treatment procedures using adjuvant or combination treatment is a novel strategy to increase the efficiency of chemotherapy. PPM1D is a molecule activated by reactive oxygen species. whose expression is reported to modulate the recruitment of DNA repair molecules. In this study we examined the impact of arsenic trioxide on efficacy of paclitaxel-induced apoptosis in paclitaxel-resistant MCF-7 cells. We also investigated the expression of PPM1D and TP53 genes in response to this combination treatment. Resistant cells were developed from the parent MCF-7 cell line by applying increasing concentrations of paclitaxel. MTT assays were applied to determine the rate of cell survival. DAPI staining using fluorescent microscopy was employed to study apoptotic bodies. Real-time RT-PCR analysis was also applied to determine PPM1D mRNA levels. Our results revealed that combination of arsenic trioxide and paclitaxel elevates the efficacy of the latter in induction of apoptosis in MCF-7/PAC resistant cells. Applying arsenic trioxide also caused significant decreases in PPM1D mRNA levels (p<0.05). Our findings suggest that arsenic trioxide increases paclitaxel-induced apoptosis by down regulation of PPM1D expression. PPM1D dependent signaling can be considered as a novel target to improve the efficacy of chemotherapeutic agents in resistant breast cancer cells.